聯交所更新生物科技公司指引信
聯交所公布,昨日(10日)更新了有關生物科技公司上市文件披露事宜的指引信。更新後的指引信(HKEX-GL107-20)就相關上市申請人呈列公正、不偏不倚和準確的披露資料,以及聯交所預期根據《主板規則》第十八A章上市的生物科技公司披露若干主要業務和產品範圍資料等事宜提供指引。
港交所上市科主管陳翊庭表示,自2018年4月《上市規則》新增第十八A章以來,來自生物科技公司的上市申請宗數增長可觀,公司類型亦更見多元化。隨著香港生物科技行業的發展愈益深廣,認為有必要提供進一步指引,以提升生物科技公司上市文件的披露。
公布指,本港現時根據第十八A章在港上市的生物科技公司共有30家,合共集資780億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.